Shaping the Female Infertility Market in 2025: Rising Infertility Trends Driving Demand For Advanced Treatments

How Big Is the Female Infertility Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been a regular expansion in the market size of female infertility. The market is predicted to increase from $1.79 billion in 2024 to $1.87 billion in 2025, experiencing a compound annual growth rate (CAGR) of 4.5%. The reasons behind the growth during the historic period include the rising trend of women postponing motherhood, changing lifestyles, government initiatives, an increasing elderly population, and more utilization of assisted reproductive technology (ART) treatment.

The market size for female infertility is predicted to steadily increase in the upcoming years, reaching a valuation of $2.19 billion by 2029, with a compound annual growth rate (CAGR) of 4.1%. This growth over the forecast period is likely due to the increasing knowledge about fertility problems, a surge in polycystic ovary* syndrome cases, higher numbers of uterine abnormalities, increased reports of genetic disorders, and an increase in obesity. Trends to look out for during the forecast period would be advancements in preimplantation genetic testing, technological improvements, the advent of new diagnosis technologies, fertility preservation, and telemedicine.

What Are the Primary Growth Drivers for the Female Infertility Market?
The escalating occurrence of infertility is predicted to spur advancements in the female infertility market. Infertility, which is manifested as the inability to get pregnant after a year of regular unprotected sex, is increasingly being attributed to a range of factors such as delayed childbearing, changes in lifestyle, exposure to environmental toxins, growing obesity rates, and escalating levels of stress. Addressing these underlying medical, hormonal, or structural issues that affect fertility is crucial for infertility treatment in women, which in turn improves the likelihood of conception and avoids permanent infertility. For instance, statistics from July 2024 by the UK's Human Fertilization and Embryology Authority, a non-departmental public branch of the Department of Health and Social Care, indicate that around 77,000 fresh and frozen embryo transfer IVF cycles were conducted on 52,500 patients in licensed fertility clinics across the UK in 2022. The majority of these patients, over 90%, underwent treatment alongside a partner, equating to roughly 100,000 individuals. Hence, the rise in infertility cases fuels the growth of the female infertility market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

Who Are the Dominant Companies Influencing Female Infertility Market Trends?
Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd

Which Key Developments Are Influencing the Female Infertility Market?
Leading businesses in the female infertility sector are focusing on the creation of groundbreaking products such as non-invasive diagnostic tests, to establish a strategic advantage in the market. A non-invasive diagnostic test is a procedure used to identify medical conditions or diseases without any need for surgical intervention or body penetration. For example, in August 2024, Heranova Lifesciences, a biotech entity based in the US, introduced an early access program for a product named HerResolve, a non-invasive diagnostic assessment for endometriosis. This condition affects approximately 200 million women globally and could lead to infertility, pain, and bleeding. It typically takes 7-10 years to accurately diagnose many women due to varied symptom manifestations and the invasive nature of the most dependable diagnostic technique, namely exploratory laparoscopic surgery. However, HerResolve aims to reduce this time-consuming diagnosis process from several years to just a few months, thus leading to improved patient and healthcare results. HerResolve has been designed to significantly truncate this timeline thereby enhancing patient care and outcomes.

What Are the Different Segmentations in the Female Infertility Market?
The female infertility market covered in this report is segmented -

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate
2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)
3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin
4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole
5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

Which Region Is at the Forefront of the Female Infertility Market?
Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Female Infertility Global Market Report?

- Market Size Analysis: Analyze the female infertility Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the female infertility Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall female infertility market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the female infertility market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.